Please wait
Healthcare · Drug Manufacturers - General · Price, fundamentals, signals, and forward-looking context in one research view.
Healthcare
$451B
2.7%
72.99
Current price
$255.52
+0.0% todayUpdated 51 min ago
Open
$258.67
Previous close
$255.48
Day range
$255.08 – $259.00
Volume
N/A
73.0x P/E
Awaiting filing
2.7% yield
35/100 measured
Easy to trade
Recent price movement, key market context and the latest company information.
The latest saved price history for ABBV, with its range and direction at a glance.
AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide. The company offers Skyrizi to treat autoimmune diseases; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancers; Venclexta to treat blood cancers; Elahere to treat various cancer; and Epkinly to treat lymphoma; and Emrelis for the treatment of lung cancer. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox Cosmetic for the treatment of glabellar lines, crow's feet, forehead lines, and platysma bands; Juvederm Collection to treat volume loss in the temples, undereye, cheeks, chin, lips and lower face; Vraylar to treat schizophrenia, bipolar disorder, and depressive disorder; Duodopa to treat Parkinson's disease; Ubrelvy to treat migraine; Qulipta for episodic and chronic migraine; and Vyalev for the treatment of motor fluctuations, as well as Botox Therapeutic to treat chronic migraine, overactive bladder, spasticity, cervical dystonia, and other conditions. In addition, the company offers Ozurdex for visual impairment; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; and other eye care products, including Refresh/Optive, Xen, Durysta, and Restasis. Further, it provides Mavyret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; and Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Investors usually follow ABBV for its dividend profile, valuation signal, sector position, and upcoming company events. The goal here is not just to show numbers, but to explain what they mean in plain English.
Whisone is mixed because the bullish case is not yet strong enough to lead while there is no strong bear warning from the current data. Whisone has moderate conviction here. The final read is being balanced by the weighted scores for fundamentals, technicals, insider flow, sentiment, event flow, and liquidity.
Whisone v2 splits the read into weighted parts so the score is not just one hidden number.
Fundamentals
Growth, margins, cash flow, and valuation.
Latest net profit
$3.6B
TTM (2026-07-07)
ROE
-54.5%
Return on equity
ROA
10.5%
Return on assets
Debt / equity
-11.03
Lower is usually safer.
P/B ratio
-76.06
Useful for book value support.
Dividend yield
2.7%
Current income signal.
85/100
Direction
Range-bound
Main supports
Business quality and balance-sheet strength are supporting the outlook.
Valuation still leaves room versus fair value and analyst anchors.
Recent price and fundamentals refreshes improve signal reliability.
What can go wrong
Execution risk and market swings can still delay the forecast playing out.
Fair value
$276.59
Analyst view
Buy
Analyst target
$276.59
Forecast refresh
Updated 9h ago
Quality score
69
Growth score
50
These are the external analyst numbers and business outlook figures already synced into the company record.
No external analyst outlook is available for this company yet.
$1.64
2025-01-15
Payment: TBA | Qualification: 2025-01-15 | Yield at declaration: N/A
$1.55
2024-10-15
Payment: TBA | Qualification: 2024-10-15 | Yield at declaration: N/A
A plain-English reading of momentum, trend, volatility, range position, and trading participation.
RSI
N/A
Momentum data is not available yet.
Recent trend
Sideways
+1.8% across the latest saved price window.
Volatility
Low
Beta is 0.28. Price has historically moved more calmly than the wider market.
52-week position
84% of range
Price is trading close to its 52-week high.
Volume confirmation
N/A
Comparable volume data is not available.
ABBV may also move because the HEALTHCARE sector may move with high_energy_costs. Confidence 63%.
PMG-MAN stated the pharmaceutical sector spends a large share of revenue on energy, reducing competitiveness industry-wide.
q1_2026_gdp_growth
ABBV may also move because the HEALTHCARE sector may move with q1_2026_gdp_growth. Confidence 63%.
NBS data cited in the article shows the healthcare sector grew by 1.99% in Q1 2026 (vs 1.76% in Q1 2025), indicating sector-level growth dynamics affecting listed healthcare firms.
policy_stability_and_support
ABBV may also move because the HEALTHCARE sector may benefit from policy_stability_and_support. Confidence 60%.
The sector would benefit from extended Presidential Executive Order, dedicated energy tariffs, and policies encouraging local API production to attract investment and boost local manufacturing.
local manufacturing / import substitution
ABBV may also move because the HEALTHCARE sector may benefit from local manufacturing / import substitution. Confidence 56%.
The article notes Nigeria's pharmaceutical firms are investing in local manufacturing and import substitution to reduce dependence on foreign supply, a trend that supports domestic pharma firms' growth and access.
local_manufacturing_and_access
ABBV may also move because the HEALTHCARE sector may benefit from local_manufacturing_and_access. Confidence 56%.
MeCure's emphasis on affordable, locally manufactured medicines and wider market penetration illustrates sector-level support for improved local manufacturing and access to quality medicines.
manufacturing infrastructure
ABBV may also move because the HEALTHCARE sector may benefit from manufacturing infrastructure. Confidence 56%.
Completion of a pharmaceutical manufacturing facility by Neimeth increases manufacturing capacity in the healthcare sector.
local_manufacturing_and_product_innovation
ABBV may also move because the HEALTHCARE sector may move with local_manufacturing_and_product_innovation. Confidence 53%.
MeCure's focus on deepening local manufacturing, product innovation, and expanded market penetration reflects sector-wide themes of local production and access to affordable medicines.
profit-taking
ABBV may also move because the HEALTHCARE sector may move with profit-taking. Confidence 53%.
Profit-taking is identified in the article as a trigger for the sell-off impacting SWOOT stocks.
ABBV
AbbVie Inc.
Price: $255.52
P/E: 72.994286
Yield: 2.7%
ABT
Abbott Laboratories
Price: $112.50
P/E: 36.39806
Yield: 2.3%
ALGN
Align Technology, Inc.
Price: $157.61
P/E: 27.310226
Yield: 0.0%
AMGN
Amgen Inc.
Price: $432.46
P/E: 26.875078
Yield: 2.3%
Industry
Drug Manufacturers - General
Employees
57000
Exchange
NYQ
Ticker
ABBV
